1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

AACR: Three Promising Anticancers From Loxo Oncology, Ignyta And BeiGene

 
• By John Davis

Investigational anticancer drugs aimed at new potential targets, particularly those involving genetic abnormalities that can be identified for diagnostic purposes, were the focus of presentations on their safety and efficacy in Phase I studies at this year's American Association for Cancer Research (AACR) meeting, being held in New Orleans on Apr. 16-20.

Investigational anticancer drugs aimed at new potential targets, particularly those involving genetic abnormalities that can be identified for diagnostic purposes, were the focus of presentations on their safety and efficacy in Phase I studies at this year's American Association for Cancer Research (AACR) meeting, being held in New Orleans on Apr. 16-20.

Progress in this area should eventually allow cancer therapies to be chosen on the basis of tumor genetics, rather than on the site of the tumor in the body. New targets reaching the clinic and highlighted at AACR included a tropomyosin receptor kinase (TRK) inhibitor, a new oral tyrosine kinase inhibitor, and a RAF protein inhibitor

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

More from Therapy Areas

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.